ATE308244T1 - Dna-impfung zur behandlung von autoimmunerkrankungen - Google Patents

Dna-impfung zur behandlung von autoimmunerkrankungen

Info

Publication number
ATE308244T1
ATE308244T1 AT00912207T AT00912207T ATE308244T1 AT E308244 T1 ATE308244 T1 AT E308244T1 AT 00912207 T AT00912207 T AT 00912207T AT 00912207 T AT00912207 T AT 00912207T AT E308244 T1 ATE308244 T1 AT E308244T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
dna vaccination
treat autoimmune
vaccination
recipient
Prior art date
Application number
AT00912207T
Other languages
English (en)
Inventor
Lawrence Steinman
Pedro Jose Ruiz
Hideki Garren
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE308244T1 publication Critical patent/ATE308244T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00912207T 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen ATE308244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26759099A 1999-03-12 1999-03-12
PCT/US2000/006233 WO2000053019A1 (en) 1999-03-12 2000-03-10 Dna vaccination for treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
ATE308244T1 true ATE308244T1 (de) 2005-11-15

Family

ID=23019424

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05015105T ATE453404T1 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen
AT00912207T ATE308244T1 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05015105T ATE453404T1 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen

Country Status (9)

Country Link
EP (3) EP1168923B1 (de)
JP (1) JP2003508346A (de)
AT (2) ATE453404T1 (de)
CA (1) CA2363269C (de)
DE (2) DE60023673T2 (de)
DK (2) DK1168923T3 (de)
ES (2) ES2251974T3 (de)
PT (1) PT1621208E (de)
WO (1) WO2000053019A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2435758C (en) 2001-11-21 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy against autoantigens for treating insulin dependent diabetes mellitus
US9387226B2 (en) 2006-11-30 2016-07-12 Medipost Co., Ltd Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells
CN100571786C (zh) * 2007-03-26 2009-12-23 中国农业大学 一种预防和/或治疗自身免疫疾病的疫苗
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
JP5784754B2 (ja) 2011-02-02 2015-09-24 メディポスト・カンパニー・リミテッドＭｅｄｉｐｏｓｔ Ｃｏ．， Ｌｔｄ． 神経疾患の予防または処置のためのｉｃａｍ−１の使用
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10898590B2 (en) 2015-09-21 2021-01-26 Kolon Life Science, Inc. Method for delivery of biological molecule to nervous tissue
KR20170034701A (ko) 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
WO2023086969A2 (en) * 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891435A (en) 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
AU3225097A (en) 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease

Also Published As

Publication number Publication date
EP1168923A4 (de) 2002-06-26
EP1168923A1 (de) 2002-01-09
DK1168923T3 (da) 2006-03-20
WO2000053019A1 (en) 2000-09-14
JP2003508346A (ja) 2003-03-04
DE60023673D1 (de) 2005-12-08
DK1621208T3 (da) 2010-05-10
EP1168923B1 (de) 2005-11-02
EP2177228A1 (de) 2010-04-21
PT1621208E (pt) 2010-04-07
ATE453404T1 (de) 2010-01-15
EP1621208A1 (de) 2006-02-01
ES2251974T3 (es) 2006-05-16
EP1621208B1 (de) 2009-12-30
CA2363269C (en) 2012-06-12
ES2338890T3 (es) 2010-05-13
DE60043624D1 (de) 2010-02-11
DE60023673T2 (de) 2006-07-20
CA2363269A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
ATE308244T1 (de) Dna-impfung zur behandlung von autoimmunerkrankungen
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
HK1078777A1 (en) Modified vaccinia virus ankara for the vaccination of neonates
FI932678A (fi) Pao alfavirus baserande dna expressionssystem
DE69737969D1 (de) Dns-impfung zur einleitung einer suppressiven t-zell-antwort
EP0445228A4 (en) Immunotherapy involving cd28 stimulation
NO20024157D0 (no) Kasein-avledete peptider og anvendelser derav i terapi
ATE124959T1 (de) Herstellung und verwendung von nicht- glycosiliertem il-6.
ATE181501T1 (de) Verwendung von l-deprenyl zur hemmung des alterniedergangs des immunsystems in säugetieren
DE60334725D1 (de) N vitro zur behandlung von tumoren
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso
HUP9900681A2 (hu) TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
ATE71662T1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
Andrews et al. Homeostatic defects in interleukin 18‐deficient mice contribute to protection against the lethal effects of endotoxin
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
ATE80912T1 (de) Menschliche proteine des chinolinesterase-typs und ihre herstellung.
ATE225183T1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
ATE499383T1 (de) Eine methode zur herstellung von menschlichem natürlichem interferon-alpha
DE60043216D1 (de) Gm-csf zur behandlung von morbus crohn
UA36324A (uk) Спосіб стимуляції гемопоетичної активності кріоконсервованого аломієлотрансплантата
ATE315082T1 (de) Myeloider koloniestimulierungsfaktor und verwendungen davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1168923

Country of ref document: EP